高级检索
当前位置: 首页 > 详情页

Novel Curcumin Liposome Modified with Hyaluronan Targeting CD44 Plays an Anti-Leukemic Role in Acute Myeloid Leukemia in Vitro and in Vivo.

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ EI

机构: [1]State Key Laboratory of Biotherapy, West China Hospital, College of Life Sciences, Sichuan University and Collaborative Innovation Center of Biotherapy , Chengdu 610064, China. [2]Division of Biosciences, Faculty of Life Sciences, University College London , London WC1E 6BT, United Kingdom. [3]The Hormel Institute, University of Minnesota , Austin, Minnesota 55912, United States.
出处:
ISSN:

关键词: curcumin liposome hyaluronan acute myeloid leukemia CD44

摘要:
Curcumin has been widely used as a food additive for centuries and has been recently explored for its anti-inflammatory and antitumor properties. Although curcumin is pharmacologically safe and efficacious to certain cancers, its role against acute myeloid leukemia (AML) still remains unclear, and it lacks clinical application due to low water solubility and low in vivo bioavailability. To address these issues, we developed a novel curcumin liposome modified with hyaluronan (HA-Cur-LPs) to specifically deliver curcumin to AML by targeting CD44 on AML cell surface. When compared with free curcumin and nontargeted liposome (Cur-LPs), the HA-Cur-LPs exhibited good stability, high affinity to CD44, increased cellular uptake, and more potent activity on inhibiting AML cell proliferation. The KG-1 cell implanted AML mice had significantly delayed, or even prevented, AML progression following treatment with 50 mg/kg of curcumin dose in the HA-Cur-LPs every 2 days for 2 weeks. Mechanistically, the anti-AML effects of HA-Cur-LPs were achieved by inhibiting Akt/ERK pathways and activating caspase-dependent apoptosis. Moreover, HA-Cur-LPs played a critical role in downregulation of DNMT1 expression in AML, leading to DNA hypomethylation and reactivation of tumor suppressor genes such as miR-223. The development and assessment of the HA-Cur-LPs in this study provide another potential choice for AML therapy, using HA-Cur-LPs as either a single treatment agent or in combination with other treatments.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 1 区 工程技术
小类 | 2 区 材料科学:综合 2 区 纳米科技
最新[2023]版:
大类 | 2 区 材料科学
小类 | 2 区 材料科学:综合 2 区 纳米科技
第一作者:
第一作者机构: [1]State Key Laboratory of Biotherapy, West China Hospital, College of Life Sciences, Sichuan University and Collaborative Innovation Center of Biotherapy , Chengdu 610064, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号